The Ludwig Institute for Cancer Research (LICR) is an international non-profit research institute dedicated to improving the understanding and control of cancer. Below are highlights of the Institute’s news.
December 31, 2008
Investigators from the Ludwig Institute for Cancer Research (LICR) Melbourne Center reported today in the journal The Prostate that a potential new reagent could treat prostate tumors with greater specificity and reduced toxicity than many currently used therapies.
November 16, 2008
The international Ludwig Institute for Cancer Research (LICR) announced today that one of its spin-off companies, Life Science Pharmaceuticals, has licensed its lead cancer therapy candidate to pharmaceutical company Abbott.
October 21, 2008
In a study published this week in Nature, investigators from the Melbourne Branch of the Ludwig Institute for Cancer Research (LICR), the Institute for Molecular Bioscience (Australia) and the FIRC Institute of Molecular Oncology (Italy) report that a “genetic switch” directs the formation of new lymphatic vessels.
September 29, 2008
Dr. Bing Ren, from the LICR San Diego Branch, selected as a key grant-awardee in the five-year, USD 190 million NIH Roadmap ‘Epigenomics Program.
August 14, 2008
Investigators from the Melbourne Center of the international Ludwig Institute for Cancer Research (LICR) and Pacific Edge Biotchnology Ltd today reported that they have developed a test to predict whether a patient will progress rapidly from Stage III melanoma to metastatic Stage IV cancer and death.
August 13, 2008
Dr. Bing Ren, Associate Member of the Ludwig Institute for Cancer Research (LICR) San Diego Branch, was granted a $1.73 million New Faculty II Award by the California Institute of Regenerative Medicine (CIRM), the stem cell agency of the state.
June 21, 2008
The drug tPA is the most effective treatment currently available for stroke patients, but its safety is limited to use within the first three hours following the onset of symptoms. After that, tPA may cause dangerous bleeding in the brain. However, in a study published today in Nature Medicine, investigators from the Stockholm Branch of the Ludwig Institute for Cancer Research (LICR) and the University of Michigan show that these problems might be overcome if tPA is combined with the leukemia drug, imatinib (Gleevec®).
May 04, 2008
In a study published today in Cancer Cell, a group led by LICR Affiliate Dr. Kari Alitalo (Helsinki, Finland), identified the PROX1 protein as a key driver of colon cancer tumorigenesis.
April 27, 2008
Dr. Richard D. Kolodner, LICR Executive Director of Laboratory Science and Technology and a Member of the LICR San Diego Branch, was today elected a Fellow of the prestigious American Academy of Arts and Sciences.
April 14, 2008
PIramed, the first spin-off company from the Ludwig Institute for Cancer Research, was today acquired by the pharmaceutical company, Roche. PIramed was formed in 2003 to exploit inhibitors targeting the PI-3 kinase family of enzymes. The inhibitors - and most of the PI-3 kinases - were first characterized by a group led by the Founding Director of the LICR London Branch, Michael D. Waterfield, F.R.S.
February 11, 2008
The National Health & Medical Research Council (NHMRC) of Australia has awarded its largest grant for 2009 to the Ludwig Institute for Cancer Research (LICR) in Melbourne.
February 03, 2008
What if we could prevent cancer recurrence for years after surgery by giving simple recall injections every two or three years? This concept may no longer be a fantasy. In a clinical study published online this week by the Proceedings of the National Academy of Sciences USA, a team headed by the international Ludwig Institute for Cancer Research (LICR) has shown that a vaccine against a protein found in cancer cells produces an immune response that can be boosted and strengthened with additional vaccine shots.